Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

329.00INR
23 Apr 2019
Change (% chg)

Rs0.90 (+0.27%)
Prev Close
Rs328.10
Open
Rs329.60
Day's High
Rs330.80
Day's Low
Rs326.10
Volume
807,639
Avg. Vol
1,071,702
52-wk High
Rs432.50
52-wk Low
Rs305.95

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says Zydus Gets Final U.S. FDA Approval For Acetazolamide Injection
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM U.S. FDA FOR ACETAZOLAMIDE FOR INJECTION.  Full Article

Cadila Healthcare Says Zydus Gets Tentative USFDA Nod For Lacosamide Tablets
Monday, 8 Apr 2019 

April 8 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR LACOSAMIDE TABLETS.DRUG WILL BE MANUFACTURED AT THE GROUP'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD .LACOSAMIDE IS AN ANTICONVULSANT OR ANTIEPILEPTIC DRUG, USED TO PREVENT AND CONTROL SEIZURES.  Full Article

Cadila Healthcare Says U.S FDA Inspects Formulations Manufacturing Facility At Pharmez
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Cadila Healthcare Ltd ::U.S FDA INSPECTED CO‘S FORMULATIONS MANUFACTURING FACILITY LOCATED AT PHARMEZ, AHMEDABAD.INSPECTION CONCLUDED WITH ONE OBSERVATION.  Full Article

Cadila Healthcare Says Zydus Got USFDA Nod For Mirabegron Extended-Release Tablets
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR MIRABEGRON EXTENDED-RELEASE TABLETS.  Full Article

Cadila Healthcare Says Zydus Gets Final Approval From U.S FDA For Ambrisentan Tablets
Friday, 29 Mar 2019 

March 29 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM U.S FDA FOR AMBRISENTAN TABLETS.SAYS DRUG WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Acyclovir Ointment
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR ACYCLOVIR OINTMENT.SAYS ACYCLOVIR, AN ANTIVIRAL DRUG, WILL BE MANUFACTURED AT THE GROUP'S TOPICAL MANUFACTURING FACILITY AT AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Sitagliptin And Metformin Hydrochloride Extended-Release Tablets
Thursday, 14 Mar 2019 

March 14 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM THE USFDA FOR SITAGLIPTIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.SAYS DRUG WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare says Zydus Receives U.S. FDA Approval For Transdermal Product
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES USFDA APPROVAL FOR ITS TRANSDERMAL PRODUCT, RIVASTIGMINE TRANSDERMAL SYSTEM.GROUP ALSO RECEIVED FINAL APPROVAL FOR ROSUVASTATIN TABLETS USP IN STRENGTHS OF 5 MG, 10 MG, 20 MG, & 40 MG.  Full Article

Cadila Healthcare Vaccine Vaxirab N Gets Prequalification From WHO
Friday, 15 Feb 2019 

Feb 15 (Reuters) - Cadila Healthcare Ltd ::PURIFIED CHICK EMBRYO CELL RABIES VACCINE, VAXIRAB N, HAS RECEIVED PREQUALIFICATION FROM WORLD HEALTH ORGANISATION.  Full Article

India's Cadila Healthcare Dec-Qtr Consol Profit Falls
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Cadila Healthcare Ltd ::DEC QUARTER CONSOL NET PROFIT 5.11 BILLION RUPEES VERSUS PROFIT OF 5.43 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 4.73 BILLION RUPEES.DEC QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 35.78 BILLION RUPEES VERSUS 32.60 BILLION RUPEES LAST YEAR.  Full Article